Displaying 1 - 10 of 10
| Active Ingredient | TERBINAFINE |
| Therapeutic Class | ALLYAMINES |
| Indications | Onychomycosis.Indicated for onychomycosis of the toenail or fingernail owing to dermatophytes (tinea unguium |
| Caution |
Headache, rash , nausea, diarrhea, dyspepsia, taste disturbance, elevated liver function test results, rarely, cases of liver failure, some leading to death or liver transplant. Skin and subcutaneo More ... |
| Dose Range | 250mg once daily for 6-12 weeks. |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only if potential benefit outweighs risk. |
| Breast Feeding | Accumulation in breastmilk prohibits use. |
| Active Ingredient | CLOTRIMAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Vaginal and vulval candidiasis. |
| Caution | Local irritation and contact dermatitis may occur. |
| Dose Range | Insert one applicatorful nightly of 1% cream for 7-14 nights, 2% cream for 3 nights, 10% cream stat dose or 200mg ovules into the vagina for 3 consecutive nights or 100mg ovule for 6 nights. Continue use during menstrual period. |
| Drug Interactions | |
| Pregnancy | Pregnant women need a longer duration of treatment, usually about 7 days, to cle More ... |
| Breast Feeding |
| Active Ingredient | ECONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Yeast infections, candidiasis. |
| Caution | Burning, stinging and erythema. |
| Dose Range | 150mg once daily at bedtime for 3 consecutive nights. Continue use during menstrual period. |
| Drug Interactions | |
| Pregnancy | Pregnant women need a longer duration of treatment, usually about 7 days, to cle More ... |
| Breast Feeding |
| Active Ingredient | FLUCONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Treatment of orophary ngeal and esophageal candidiasis, systemic candidal infections, vaginal candidasis, urinary tract infections, pneumonia, and peritonitis. Also, acquired immunodeficiency syndrome More ... |
| Caution | Nausea, vomiting, diarrhoea, elevations in liver functions tests and alopecia. Low dose does not appear to increase risk of congenital abnormalities in t he first trimester. |
| Dose Range |
Oropharyngeal and esophageal candidiasis: 200mg on day 1 then 100mg PO/IV daily for at least 2 weeks. Systemic candidiasis: 400mg PO/IV once daily for 4 weeks and for at least 2 weeks orally after resolution of symptoms. Vaginal candidiasis: 150mg ora |
| Drug Interactions | Clindamycin, Calcium channel blockers, Phenothiazines and Tricyclic antidepressants - increased risk of cardiotoxicity. Simvastatin and Cerivastatin - increased risk of Rhabdomyolysis. Amlodipi More ... |
| Pregnancy | Avoid use in pregnancy. Multiple congenital abnormalities has been reported with More ... |
| Breast Feeding |
| Active Ingredient | ISOCONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ITRACONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Treatment of vulvovaginal candidiasis, dermatophytoses unresponsive to topical treatment, systemic infections. |
| Caution |
Abdominal pain; diarrhoea, dysnoea; headache; hepatitis; hypokalaemia; nausea; rash; taste disturbances; vomiting. Itraconazole should be avoided in patients with ventricular dysfunction or a history More ... |
| Dose Range | Adult: Vulvovaginal candidiasis: 200mg twice daily for 1 day , Recurrent Vulvovaginal candidiasis: 50-100mg daily for 6 months. Systemic candidiasis: 100-200mg once daily . |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only in lifethreatening situations (toxicity at high do More ... |
| Breast Feeding | Small amounts present in milkâmay accumulate; manufacturer advises avoid. |
| Active Ingredient | ITRACONAZOLE | SECNIDAZOLE |
| Therapeutic Class | AZOLES |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | KETOCONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Vaginal candidiasis; prophylaxis of mycoses in immunosuppessed patients; systemic mycoses. To be used only in those patients who are resistant to fluconazole or terbinafine. |
| Caution | Local irritation. Use with caution in patients with impaired hepatic function or adrenal reserve; blood dyscrasias, headache, dizziness, nausea, skin rash. The oral form may be taken with food or milk More ... |
| Dose Range | Vaginal candidiasis: One ovule into the vagina at bedtime for 3 consecutive nights. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MICONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Vaginal candidiasis |
| Caution | Vaginal burning, irritation, contact dermatitis. |
| Dose Range | One applicator full at night for 7 nights or 1 ovule at night for 3 nights. |
| Drug Interactions | |
| Pregnancy |
Pregnant women need a longer duration of treatment, usually about 7 days, to cle More ... |
| Breast Feeding |
| Active Ingredient | VORICONAZOLE |
| Therapeutic Class | AZOLES |
| Indications | Invasive aspergillosis in immunocompromised patients; candidaemia, in non-neutropenic patients, fluconazole-resistant serious invasive candidiasis, oesophageal candidiasis, and serious fungal infecti More ... |
| Caution | Visual disturbances, fever, rashes, nausea, vomiting, diarrhoea, abdominal pain, headache, sepsis, respiratory disorders, and peripheral oedema. |
| Dose Range |
IV: adults and adolescents: 6 mg/kg every 12 hours for the first 24 hours followed by maintenance dose of 4 mg/kg twice daily ; a lower dose of 3 mg/kg twice daily may be suitable for candidaemia in non- neutropenic patients or for deep tissue C |
| Drug Interactions | |
| Pregnancy | Because voriconazole can cause fetal harm, it should not be used during pregnanc More ... |
| Breast Feeding | It is not known whether voriconazole is distributed into milk. |